We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A majority of patent settlements reached last year in the European Union restricted the market entry of generics, according to a European Commission report. Read More
Drugmakers have expressed concern about the German government’s proposal to restrict drug pricing — contending that the measure penalizes research and development. Read More
After the FDA clamped down on its facilities most of the year, Lupin has received clearance from the agency to produce drugs again at its site in Goa, India. Read More
The U.S. government and life sciences industry groups have asked Japan not to change the country’s drug pricing system to annual price reviews and cuts, instead of the current two-year review. Read More
The FTC is urging a D.C. federal court not to postpone an order that requires Boehringer Ingelheim to hand over documents in a pay-for-delay lawsuit involving the blood thinner, Aggrenox. Read More
A federal judge awarded the Federal Trade Commission its request to dismiss a pay-for-delay suit that alleges generics drugmaker Watson Laboratories entered an illegal deal with Endo to block the market entry of Opana ER and Lidoderm generics. Read More
The U.S. Supreme Court has paved the way for non-cash patent settlements, which are often reached by branded and generics drugmakers, to trigger antitrust scrutiny after it refused to hear a case involving GlaxoSmithKline’s epilepsy therapy Lamictal. Read More
A federal judge ruled that a generic version of Merck’s Nasonex developed by Teva Pharmaceuticals does not infringe patent claims covering the allergy treatment’s active ingredient. Read More
The PTO’s Patient Trial and Appeal Board said it was not persuaded by Coherus Biosciences’ challenge over the patentability of methods for manufacturing Humira, and ruled in favor of AbbVie in a trial proceeding. Read More
The antitrust division of the Justice Department has issued subpoenas to a Mylan executive and certain employees over the pricing of four generic drugs. Read More